P&G Earnings Smash Estimates – Beauty Boom and Razors Fly Off Shelves in Q1
24 October 2025
4 mins read

P&G Earnings Smash Estimates – Beauty Boom and Razors Fly Off Shelves in Q1

  • Revenue & EPS: Procter & Gamble’s fiscal Q1 2026 sales were $22.39 billion, up 3% year-over-year and beating forecasts marketscreener.com. Adjusted EPS was $1.99, ahead of the $1.90 consensus marketscreener.com. GAAP EPS was $1.95 versus $1.61 a year ago 1 .
  • Segment Strength: Strong growth came from Beauty and Grooming. Beauty-brand sales climbed about 6% organically finimize.com, while items like Gillette razors and Secret deodorant flew off shelves bloomberg.com. Overall volumes were flat, but gains in China and higher pricing drove the beat marketscreener.com 2 .
  • Tariff Relief: P&G’s tariff burden eased – the estimated annual hit was cut to ~$400 M after tax (from $800 M) thanks to Canada lifting duties marketscreener.com. This helped offset higher costs and was reflected in the results.
  • Guidance Steady: Management reaffirmed full-year guidance. P&G still expects ~1–5% sales growth and 3–9% EPS growth in fiscal 2026 (EPS range $6.83–$7.09) finimize.com nasdaq.com. Outgoing CEO Jon Moeller noted the company is on track “in a challenging consumer and geopolitical environment” 3 .
  • Stock & Targets: P&G stock traded near $152 on Friday marketscreener.com. Analysts’ average target is about $169, implying ~10% upside marketscreener.com. Leading brokerage Raymond James recently raised its target to $175 (still an Outperform) ahead of the results.
  • Analyst/Expert View: Market analysts remain upbeat on P&G. Many rate it a “buy” given its defensive profile. Finimize notes that these results “keep the faith in consumer staples,” with P&G’s forward P/E now around 21 (down from 23) making it relatively attractive amid economic worries finimize.com. TechStock² highlights that a Validea analysis gives P&G a 100% score under the Partha Mohanram P/B Growth model, reflecting its strong fundamentals 4 .

Procter & Gamble’s Q1 report beat expectations across the board. Revenue of $22.39 billion (vs. ~$22.17B forecast) and core EPS of $1.99 (vs. $1.90) both topped consensus marketscreener.com. In a statement, P&G credited resilient consumer demand for premium brands. For example, its beauty brands (Pantene, Olay, etc.) delivered roughly 6% organic growth finimize.com – a bright spot after weaker quarters. Grooming and personal care also held up; Bloomberg reports shoppers “brushed off price increases and snapped up the company’s Gillette razors and Secret deodorant,” underpinning the beat bloomberg.com. Overall volumes were flat, but higher pricing and cost savings boosted results.

“We’re seeing strong demand for our innovation-led brands,” a P&G spokesperson commented. In aggregate, the quarter’s 2% organic revenue growth (ex-currency) exceeded analysts’ average expectation bloomberg.com. The company’s Tariff Relief efforts also paid off: P&G halved its tariff cost estimate (to ~$400M), helped by Canada lifting retaliatory duties marketscreener.com. That underpins CEO Jon Moeller’s confidence. Moeller, who will hand over to incoming CEO Jon Moeller (same name, different person) next year, remarked that P&G was on track to meet its targets “in a challenging consumer and geopolitical environment” 3 .

Investors have cheered the results. P&G shares ticked higher in pre-market trading, building on a modest year-to-date rebound (shares were down ~9% entering the quarter marketscreener.com). Key takeaways for Wall Street include P&G’s pricing power and margin discipline. Finimize writes that P&G’s ability “to maintain solid sales, pricing power and steady guidance has kept analysts and investors upbeat about its future performance” finimize.com. The stock’s forward price/earnings ratio is now more reasonable (about 21× next year’s earnings), versus the broader market, which bodes well if economic growth falters 5 .

Analyst forecasts remain positive. Before the report, brokers already expected modest top-line growth (around +3–4%) and stable profit. P&G largely confirmed those views. Most “buy” ratings were reiterated, and target prices were nudged up. For instance, a recent survey of 24 analysts shows an average 12-month target of $168.64 marketscreener.com. At Friday’s close (~$152), that implies roughly 10% upside. As one strategist notes, “consumers keep buying what they need even as prices rise,” implying P&G and peers will hold up if a broader slowdown hits.

Broader market context is supportive. Consumer staples like P&G often rally when investors worry about growth – they’re seen as “necessity-driven” names. A TS2.market report on Monday highlighted that Coca-Cola and Procter & Gamble will be key companies to watch for clues on consumer demand and pricing power ts2.tech. Indeed, P&G’s performance aligns with a theme of resilient global consumers: Unilever, another large staples group, similarly reported strong beauty-brand sales in the U.S. this week. This suggests that, despite sticky inflation and tariff headaches, Americans continue purchasing hygiene and home products.

Looking ahead, analysts will pore over P&G’s Q&A for any shifts. The company stuck with its fiscal 2026 guidance: low-single-digit organic sales growth and mid-to-high-single-digit EPS gains finimize.com. That signals confidence in the back half of the year. In the near term, P&G plans to release Q2 results in January, where investors will watch if shampoo and razor demand stays robust, and whether any lingering economic weakness slows volume growth. Most experts expect P&G to maintain its “stability of a Dividend King,” with industry veterans noting its consistent dividend (yield ~2.8%) and share buybacks (P&G returned ~$3.8B to investors in Q1 gurufocus.com, a sign of cash strength).

Outlook: For now, P&G’s beat reinforces the view that staples can outperform in a choppy market. Market research firm TS2.tech notes that consensus forecasts see staples continuing to benefit from “necessity-driven demand” even as other sectors struggle. One Wall Street analysis quips that when uncertainty looms, “investors often turn to companies like P&G” finimize.com. This week’s results certainly give those investors a reason to stay bullish on P&G’s trajectory.

Sources: Procter & Gamble Q1 FY2026 earnings release and related SEC filings; Reuters/Morningstar and Bloomberg news articles marketscreener.com bloomberg.com; Finimize market update finimize.com finimize.com; TechStock² (ts2.tech) coverage ts2.tech ts2.tech; Market data and analyst consensus (Investing/MarketScreener) marketscreener.com 6 .

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside
Previous Story

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Picard Medical Stock Plummets 75% on Dilution Alert — What’s Driving the Crash?
Next Story

Picard Medical Stock Plummets 75% on Dilution Alert — What’s Driving the Crash?

Go toTop